As part of its ongoing support to Member States, the World Health Organization (WHO) has provided the Federated States of Micronesia (FSM) Department of Health and Social Affairs (DHSA) with its annual supply of Multidrug Therapy (MDT) medicines for leprosy. In addition, WHO handed over GeneXpert Flu/SC2/RSV cartridges: advanced diagnostic tools that enable simultaneous testing for influenza, SARS-CoV-2, and respiratory syncytial virus (RSV). These life-saving medications will be distributed across FSM’s four states: Yap, Chuuk, Pohnpei, and Kosrae, to ensure timely treatment and support for individuals affected by leprosy.
The donation was officially received by the Acting Secretary on behalf of DHSA, during a brief handover ceremony held in Pohnpei. Representing WHO was Dr. Sam Fullman, who reaffirmed WHO’s commitment to supporting FSM’s efforts to eliminate neglected tropical diseases and strengthen disease surveillance and response capacity.
Leprosy, also known as Hansen’s disease, is a chronic infectious disease caused by Mycobacterium leprae. It primarily affects the skin, peripheral nerves, and eyes, and if left untreated, can lead to permanent disabilities. However, leprosy is curable, and early treatment with MDT can prevent disability and halt transmission.
FSM has made commendable progress in reducing the burden of leprosy, but continued vigilance is essential. The donated medicines will strengthen the country’s capacity to detect and treat cases early, especially in remote communities where access to healthcare can be limited. The Mpox cartridges will further enhance FSM’s ability to respond to emerging health threats through rapid and accurate testing.
“This donation from WHO is more than just medicine and laboratory supplies; it’s a symbol of solidarity and shared commitment to health equity,” said T.H. Kasinda Ludwig, Acting Secretary, Department of Health and Social Affairs, FSM. “With these new treatments and testing supplies, we are better equipped to serve our communities in Yap, Chuuk, Pohnpei, and Kosrae. It means we can ensure diseases like leprosy aren’t just managed but are on the path to being eliminated from our islands. Our new multiplex PCR capabilities, like the GeneXpert for Flu, COVID-19, and RSV, allow for rapid, accurate diagnosis. This is critical for early outbreak containment, helping to reduce the rate of severe clinical presentations and the overall strain on our healthcare system.”
“Leprosy is curable, and no one should suffer its consequences in silence,” said Dr. Roderico Ofrin, WHO Representative. “By supporting FSM with these essential medicines and diagnostic tools, we are reinforcing our partnership and helping ensure that even the most remote communities have access to timely and effective care.”
This donation reflects the strong collaboration between the FSM Department of Health and Social Affairs and the World Health Organization. It supports FSM’s efforts to eliminate leprosy and strengthen disease surveillance, while aligning with WHO’s Global Leprosy Strategy 2021–2030, which envisions zero disease, zero disability, and zero discrimination. Together, FSM and WHO are working toward a healthier future for all communities across the Pacific.